{"id":"trastuzumab-h","safety":{"commonSideEffects":[{"rate":"5-27%","effect":"Cardiotoxicity / left ventricular dysfunction"},{"rate":"20-40%","effect":"Infusion reactions"},{"rate":"20-30%","effect":"Diarrhea"},{"rate":"20-25%","effect":"Nausea"},{"rate":"15-25%","effect":"Fatigue"},{"rate":"10-15%","effect":"Headache"},{"rate":"10-15%","effect":"Fever"}]},"_chembl":null,"_dailymed":{"setId":"ebf30894-41cf-480c-8bc3-56f592a13813","title":"HERCEPTIN HYLECTA (TRASTUZUMAB AND HYALURONIDASE-OYSK) INJECTION, SOLUTION [GENENTECH, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Trastuzumab targets human epidermal growth factor receptor 2 (HER2), a protein overexpressed in certain cancers. By binding to HER2, it prevents ligand-induced signaling and recruits immune cells to destroy HER2-positive tumor cells through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).","oneSentence":"Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:55.624Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive metastatic breast cancer"},{"name":"HER2-positive early-stage breast cancer (adjuvant therapy)"},{"name":"HER2-positive metastatic gastric cancer"}]},"trialDetails":[{"nctId":"NCT07043725","phase":"PHASE3","title":"A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-09-15","conditions":"HER2-positive Breast Cancer","enrollment":544},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT02693535","phase":"PHASE2","title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","status":"RECRUITING","sponsor":"American Society of Clinical Oncology","startDate":"2016-03-14","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":4200},{"nctId":"NCT06324357","phase":"PHASE1, PHASE2","title":"Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-06-03","conditions":"Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":768},{"nctId":"NCT06649331","phase":"PHASE2","title":"Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-10-21","conditions":"Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC)","enrollment":160},{"nctId":"NCT06731803","phase":"PHASE1, PHASE2","title":"Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2025-03-25","conditions":"Esophagogastric Adenocarcinoma","enrollment":36},{"nctId":"NCT05845450","phase":"PHASE2","title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-11","conditions":"Colorectal Cancer, Resectable Colorectal Carcinoma","enrollment":197},{"nctId":"NCT04589845","phase":"PHASE2","title":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-01-18","conditions":"Solid Tumors","enrollment":920},{"nctId":"NCT05376878","phase":"PHASE4","title":"An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-12-21","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain","enrollment":10},{"nctId":"NCT02624973","phase":"PHASE2","title":"PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2016-04-15","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT05062889","phase":"PHASE2","title":"Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients","status":"SUSPENDED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-17","conditions":"Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer","enrollment":477},{"nctId":"NCT03803553","phase":"PHASE3","title":"Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-04-16","conditions":"Metastatic Colon Cancer, Stage III Colon Cancer","enrollment":400},{"nctId":"NCT05180006","phase":"PHASE2","title":"Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy","status":"TERMINATED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2022-02-24","conditions":"Breast Cancer","enrollment":33},{"nctId":"NCT07239271","phase":"PHASE3","title":"A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation Model","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-11-16","conditions":"Patients With HER2-positive Breast Cancer (BC) Suitable for Neoadjuvant Therapy","enrollment":2000},{"nctId":"NCT06533826","phase":"PHASE2","title":"TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd","status":"RECRUITING","sponsor":"Ana C Garrido-Castro, MD","startDate":"2024-10-29","conditions":"Breast Cancer, HER2-low Breast Cancer, Metastatic Breast Cancer","enrollment":357},{"nctId":"NCT04486352","phase":"PHASE1, PHASE2","title":"A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer","status":"RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2021-10-20","conditions":"Endometrial Cancer","enrollment":148},{"nctId":"NCT06490536","phase":"PHASE3","title":"The Sagittarius Trial","status":"RECRUITING","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","startDate":"2024-10-22","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":700},{"nctId":"NCT07134153","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-04-18","conditions":"Breast Cancer","enrollment":139},{"nctId":"NCT03432741","phase":"PHASE1","title":"Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2018-03-27","conditions":"Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma","enrollment":17},{"nctId":"NCT05097599","phase":"PHASE2","title":"StrataPATH™ (Precision Indications for Approved Therapies)","status":"TERMINATED","sponsor":"Strata Oncology","startDate":"2022-04-29","conditions":"Cancer, Advanced Solid Tumor","enrollment":11},{"nctId":"NCT04632992","phase":"PHASE2","title":"A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2021-01-13","conditions":"Advanced Unresectable or Metastatic Solid Malignancy","enrollment":252},{"nctId":"NCT02578368","phase":"PHASE3","title":"Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction","status":"COMPLETED","sponsor":"Krankenhaus Nordwest","startDate":"2016-02","conditions":"Gastric Cancer","enrollment":183},{"nctId":"NCT05715931","phase":"PHASE2","title":"Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Yu jiren","startDate":"2023-02-28","conditions":"Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, HER2-positive Gastric Cancer","enrollment":30},{"nctId":"NCT06435104","phase":"PHASE2","title":"Aromatherapy in the Treatment of Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-07","conditions":"Early Breast Cancer","enrollment":30},{"nctId":"NCT02291289","phase":"PHASE2","title":"A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-04-17","conditions":"Colorectal Cancer","enrollment":1044},{"nctId":"NCT06330012","phase":"NA","title":"The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.","status":"RECRUITING","sponsor":"Samsung Medical Center","startDate":"2024-03-18","conditions":"HER2-positive Breast Cancer","enrollment":50},{"nctId":"NCT03595592","phase":"PHASE3","title":"Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Michelangelo","startDate":"2018-09-07","conditions":"Invasive Breast Cancer","enrollment":650},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT05159193","phase":"PHASE3","title":"Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-12-20","conditions":"Breast Cancer","enrollment":372},{"nctId":"NCT03674112","phase":"PHASE2","title":"A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-12-19","conditions":"HER2-Positive Early Breast Cancer","enrollment":160},{"nctId":"NCT04172259","phase":"PHASE2","title":"ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-01-10","conditions":"Breast Cancer, Neoadjuvant Chemotherapy","enrollment":156},{"nctId":"NCT05955833","phase":"PHASE1","title":"89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2023-06-26","conditions":"Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer","enrollment":6},{"nctId":"NCT03988036","phase":"PHASE2","title":"A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)","status":"COMPLETED","sponsor":"West German Study Group","startDate":"2020-08-18","conditions":"Breast Cancer","enrollment":46},{"nctId":"NCT05839288","phase":"","title":"Pyrotinib Plus Trastuzumab and Chemotherapy in HER2+ Metastatic Breast Cancer Patients","status":"COMPLETED","sponsor":"Fudan University","startDate":"2022-11-01","conditions":"Breast Cancer","enrollment":161},{"nctId":"NCT05430347","phase":"PHASE2","title":"Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-04-15","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT03705429","phase":"PHASE3","title":"A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2019-05-01","conditions":"Breast Neoplasms","enrollment":51},{"nctId":"NCT05444647","phase":"","title":"Gut Microbiome Components Predict Response to Neoadjuvant Therapy in HER2-positive Breast Cancer Patients : A Prospective Study","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-07","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT04395508","phase":"","title":"An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic","status":"APPROVED_FOR_MARKETING","sponsor":"Genentech, Inc.","startDate":"","conditions":"HER2-positive Breast Cancer","enrollment":""},{"nctId":"NCT05167643","phase":"NA","title":"H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-01-23","conditions":"Advanced HR+ HER2 Negative Breast Carcinoma","enrollment":40},{"nctId":"NCT05189067","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-01-31","conditions":"HER2-positive Breast Cancer, Adjuvant Therapy","enrollment":190},{"nctId":"NCT04717531","phase":"PHASE2","title":"Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-06-03","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT00004067","phase":"PHASE3","title":"Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2000-02","conditions":"Breast Cancer","enrollment":2130},{"nctId":"NCT00625898","phase":"PHASE3","title":"BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab","status":"TERMINATED","sponsor":"NSABP Foundation Inc","startDate":"2008-04","conditions":"Breast Cancer","enrollment":3509},{"nctId":"NCT00047255","phase":"PHASE3","title":"Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2002-05","conditions":"Breast Cancer","enrollment":263},{"nctId":"NCT04302441","phase":"PHASE2","title":"A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2016-11-10","conditions":"Breast Cancer","enrollment":550},{"nctId":"NCT01827163","phase":"PHASE2","title":"Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-04","conditions":"HER2-Positive Early Stage Breast Cancer","enrollment":20},{"nctId":"NCT01679743","phase":"PHASE2","title":"GRN1005 for Brain Metastases From Breast or Lung Cancer","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2012-08-29","conditions":"Breast Cancer, Lung Neoplasms, Breast Neoplasms","enrollment":""},{"nctId":"NCT01104935","phase":"PHASE3","title":"National Surgical Adjuvant Study of Breast Cancer(N-SAS BC) 07 [RESPECT]","status":"COMPLETED","sponsor":"Comprehensive Support Project for Oncology Research","startDate":"2009-10-28","conditions":"Breast Cancer","enrollment":275},{"nctId":"NCT00681993","phase":"NA","title":"Trial of Partial Breast Irradiation With Various Concurrent Chemotherapy Regimens","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2008-04","conditions":"Breast Cancer","enrollment":35},{"nctId":"NCT01501487","phase":"PHASE4","title":"MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I","status":"COMPLETED","sponsor":"Agendia","startDate":"2011-10","conditions":"Breast Cancer","enrollment":226},{"nctId":"NCT02379585","phase":"PHASE1, PHASE2","title":"Fasting on Newly Diagnosed Breast Cancer","status":"TERMINATED","sponsor":"Western Regional Medical Center","startDate":"2013-01","conditions":"HER2-positive Breast Cancer","enrollment":8},{"nctId":"NCT00256243","phase":"PHASE2","title":"Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer","status":"COMPLETED","sponsor":"Rita Sanghvi, Mehta","startDate":"2004-04","conditions":"Breast Cancer","enrollment":48},{"nctId":"NCT02345772","phase":"PHASE1, PHASE2","title":"Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy","status":"TERMINATED","sponsor":"Western Regional Medical Center","startDate":"2014-07","conditions":"HER2-positive Breast Cancer, ER-positive Breast Cancer","enrollment":4},{"nctId":"NCT01472029","phase":"PHASE2","title":"Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2011-12","conditions":"Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach","enrollment":53},{"nctId":"NCT00550771","phase":"PHASE2","title":"Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07-16","conditions":"Breast Neoplasm","enrollment":181},{"nctId":"NCT00482391","phase":"PHASE2","title":"Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-03","conditions":"Breast Cancer","enrollment":95},{"nctId":"NCT03024450","phase":"","title":"Trastuzumab Based Therapy in HER2 Positive AGC","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2012-01","conditions":"Gastric Adenocarcinoma","enrollment":98},{"nctId":"NCT03006614","phase":"PHASE3","title":"PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer","status":"UNKNOWN","sponsor":"Shi Yanxia","startDate":"2016-04","conditions":"Breast Cancer Model, Effects of Chemotherapy, Breast Cancer","enrollment":320},{"nctId":"NCT00493649","phase":"PHASE2","title":"Adj TC + Herceptin Early Stage Breast Cancer","status":"COMPLETED","sponsor":"US Oncology Research","startDate":"2007-06","conditions":"Breast Cancer","enrollment":493},{"nctId":"NCT00567554","phase":"PHASE3","title":"Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2007-10","conditions":"Breast Cancer","enrollment":2600},{"nctId":"NCT00769470","phase":"PHASE2","title":"Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"Translational Oncology Research International","startDate":"2009-04","conditions":"Breast Cancer","enrollment":18},{"nctId":"NCT01503983","phase":"PHASE2","title":"Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive","status":"COMPLETED","sponsor":"Fundación para el Progreso de la Oncología en Cantabria","startDate":"2011-08","conditions":"Stage IV Gastric Cancer With Metastasis","enrollment":45},{"nctId":"NCT00615602","phase":"PHASE3","title":"Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer","status":"COMPLETED","sponsor":"Hellenic Oncology Research Group","startDate":"2004-10","conditions":"Breast Cancer","enrollment":489},{"nctId":"NCT00016276","phase":"PHASE3","title":"Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-05","conditions":"Cardiac Toxicity, Inflammatory Breast Cancer, Stage IIIA Breast Cancer","enrollment":396}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":748,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["qutuozhudankang"],"phase":"marketed","status":"active","brandName":"trastuzumab (H)","genericName":"trastuzumab (H)","companyName":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","companyId":"sun-yat-sen-memorial-hospital-of-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Trastuzumab is used to treat various stages of breast cancer, including Stage IIIA, Stage IIIB, and Stage IV, as well as Inflammatory Breast Cancer. It is often administered in combination with other treatments such as doxorubicin hydrochloride and cyclophosphamide.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}